Founder steps down as MicroPort launches governance review
The medical device maker has announced leadership changes as it struggles to shake off a controversy over hefty rents paid to a firm linked to its founder’s family Key Takeaways:…
CStone’s CS2009 trispecific antibody reinforces three clinical validations at ESMO
With data from over 300 patients across multiple tumor types and Phase 3 trials coming soon, the evidence supports CS2009’s mechanism, safety and antitumor efficacy Key Takeaways: CS2009 delivered strong…
Akeso’s overseas drug promise fails to slow share decline
The Chinese drugmaker has been under pressure on equity markets since revealing plans for a share placement, overriding positive news for its key cancer therapy Key takeaways: Akeso’s shares have…
AcroBiosystems leans on overseas sales in renewed Hong Kong listing bid
The company leads the field for recombinant proteins among its domestic peers, but overseas companies dominate the international market Key Takeaways: AcroBiosystems has applied to list in Hong Kong, reporting…
Pomdoctor lands in crosshairs of Nasdaq’s ‘pump and dump’ cleanup
The company has been targeted in an aggressive two-year-old campaign to delist suspicious Chinese companies from Wall Street Key Takeaways: Pomdoctor said it has been notified by the Nasdaq that…
Hengrui makes headway with novel drugs but investors bide their time
A cancer drug developed by the Chinese firm has entered the European regulatory process and Novo Nordisk has bought rights to a potential weight-loss therapy Key Takeaways: Hengrui Pharma’s cancer…
Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
The Chinese firm has lost its regulatory approval to sell a lung cancer drug in Europe over a data-protection error, and must reset the clock on the launch process Key…
